Tenon Medical

TNON

Market cap $10.5M

~ Clinically Significant Patient Outcomes Demonstrate Improvements in Pain (VAS) and Disability (ODI), Along with High Patient Satisfaction and Safety Profile at 12-Month Analysis ~ ~ 83% of Patients Reaching 12 Month Radiographic CT Follow-up Showed Unequivocal Evidence of Fusion with Bridging Bone Across the SI Joint as Identified by an Independent Radiology Reviewer ~ ~Compelling Clinical Data from Catamaran Mainsail Study and Recently Acquired SiVantage Technology Portfolio Expected to Drive Exponential Growth in Rapidly Expanding Sacro-Pelvic Fusion Market ~ LOS GATOS, CA / ACCESS Newswire / September 4, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacro-pelvic disorders, today announced the second interim analysis publication from its ongoing MAINSAIL™ study, a prospective, single-arm, multi-center, post-market clinical trial evaluating clinical and radiographic outcomes in adult patients with sacroiliac (SI) joint disruptions or degenerative sacroiliitis treated with the Catamaran® SI Joint Fusion System. The Mainsail study is designed to enroll up to 50 patients, each followed for up to 24 months.

~Full Commercial Launch with Expanded Number of Instrument Sets and Field Support to Meet Growing Market Demand ~ ~ New SI Joint Fixation Device Offers a Reduced Profile in Implant Size Providing Physicians Choices for Varying Anatomy and Treatment Strategies with the Catamaran Technology ~ LOS GATOS, CA / ACCESS Newswire / August 19, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain sacro-pelvic disorders, today announced the full commercial market launch of its new Catamaran® SE SI Joint Fusion System. The Catamaran SE Fixation Device expands the Company's implant portfolio, providing physicians with a smaller implant option for sacroiliac (SI) joint fusion procedures.

Tenon Medical, Inc. (NASDAQ:TNON ) Q2 2025 Earnings Conference Call August 13, 2025 4:30 PM ET Company Participants Kevin Williamson - Chief Financial Officer Steven M. Foster - CEO, President & Director Conference Call Participants Nicholas Sherwood - Maxim Group LLC, Research Division Scott Robert Henry - Alliance Global Partners, Research Division Operator Greetings, and welcome to the Tenon, Inc. Second Quarter 2025 Earnings Conference Call.

Image source: The Motley Fool.

~ Recently Announced Strategic Acquisition of SiVantage Portfolio Energizes Tenon's Commercial Organization and Accelerates Topline Growth ~ ~ FDA Clearance Unlocks New Sacro-Pelvic Market Opportunity for Catamaran® as Adjunct to Thoracolumbar Fixation with Initial Case Series Successfully Completed ~ ~ Operating Expenses Down 29% Year-over-Year as Company Advances Toward Integration of SiVantage Assets, Addition of Commercial Team, and full Commercial Launch of Catamaran SE ~ ~ Cash on Hand of Approximately $7.8 Million at Quarter End ~ LOS GATOS, CA / ACCESS Newswire / August 13, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today reported financial results for the second quarter ended June 30, 2025. Financial Results and Business Updates Second Quarter 2025 Results: Revenue of $0.6 million, compared to $0.9 million in the second quarter of 2024.

LOS GATOS, CA / ACCESS Newswire / August 5, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced plans to release financial results for the second quarter 2025 ended June 30, 2025 after market close on Wednesday, August 13, 2025. The Company will also hold a conference call on the same day at 4:30 p.m.

~ SiVantage Portfolio Acquisition Enhances Tenon's Sacroiliac Joint Fusion Capabilities with a Unique Multi-Product, Multi-Approach Solution ~ ~ Significant Enhancement of Tenon Medical's Commercial Leadership to Accelerate Growth Initiatives ~ ~ Reinforces Tenon's Commitment to Fusion-Driven Innovation and Data-Backed Outcomes in a Rapidly Evolving Market ~ LOS GATOS, CA / ACCESS Newswire / August 1, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical technology company dedicated to transforming care for patients with sacroiliac joint (SIJ) disorders, today announced it has acquired sacroiliac (SI) joint specific assets from SiVantage, a privately held startup company based in Tampa, Florida. This strategic asset acquisition includes SiVantage's SImmetry® and SImmetry+™ technologies expanding Tenon's SI portfolio across multiple approaches to the variable sacro pelvic anatomy.

~ Andrew J. Trontis, MD from Progressive Spine and Orthopaedics, (Englewood, NJ) Completes Initial Case Series ~ LOS GATOS, CA / ACCESS Newswire / June 12, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced the completion of an initial case series utilizing the Catamaran® SI Joint Fusion System (the "Catamaran") to immobilize & stabilize the SI Joint providing added support at the base of a lumbar or thoracolumbar fusion.

Tenon Medical, Inc. (NASDAQ:TNON ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Steve Foster - President & Chief Executive Officer Kevin Williamson - Chief Financial Officer Conference Call Participants Scott Henry - Alliance Global Partners Nicholas Sherwood - Maxim Group Operator Greetings. And welcome to the Tenon Medical First Quarter 2025 Financial Results and Corporate Update Conference Call.

~ FDA Clearance of Catamaran® SI Joint Fusion System for New Indication to Augment Spinal Fusion ~ ~ Catamaran® SI Joint Fusion Technology Protected with Robust Patent Portfolio of Twelve U.S. and International Patents ~ ~ Received Gross Proceeds of ~$7.0 Million from Equity Financing Transactions ~ ~ National Commercial Launch of Catamaran SE in Mid-2025 ~ LOS GATOS, CA / ACCESS Newswire / May 13, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today reported financial results for the first quarter ended March 31, 2025. Financial Results and Business Updates First Quarter 2025 Results: Revenue of $0.7 million, in line with the first quarter of 2024.